Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-ABH2 SPECT/CT for HER2+ Breast Cancer
NCT03546478Phase 1Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2015
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 99mTc-labeled HER2 affibody in breast cancer, sponsored by Peking Union Medical College Hospital. Primary endpoint: Target-to-Background Ratio at 1 year. Started Jun 2015; status: completed.
02
Drugs
99mTc-labeled HER2 affibody
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03546478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546478.